Our Work in Neurology
Specialized patient populations that require unique or complex therapies will continue to make neurology the target for dynamic research and commercial markets. With a specific focus on the multiple sclerosis (MS) market in the US and the EU, Spherix is shedding light on the key dynamic issues in this fast moving category as the increased risk tolerance and the expanding number of therapies evolves the treatment strategies for all forms of MS.
Multiple Sclerosis, Rare Neurological Diseases
Board of Advisors
The primary objectives of advocacy groups are to educate, advocate, collaborate, and improve the efficiency of services for individuals with MS and those who are close to them.
Recent Chart Audit of Multiple Sclerosis Patients Recently Switched to a New Disease-Modifying Therapy Shines Spotlight on Gains by Genentech’s Ocrevus in the Secondary Progressive and Primary Progressive Patient Segments – April 25, 2018
Uptake of Merck KGaA’s Mavenclad in the European Multiple Sclerosis Market Currently Stalled Due to Restrictive Guidelines and Pending Additional Country-Level Approvals – March 27, 2018
Genentech’s Ocrevus Begins to Move the Needle on the Treatment Rate for Primary Progressive Multiple Sclerosis but May Not Be the Only Disease-Modifying Therapy in Play – March 13, 2018
2018 CMSC Annual Meeting